Overview

A Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz

Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
Efavirenz is predominantly metabolized by cytochrome P450 (CYP) 2B6. Fenofibric Acid is an inhibitor of CYP2B6. This study will evaluate the effect of multiple doses of fenofibric acid at steady-state on the pharmacokinetics of single-dose efavirenz in healthy adult subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Mutual Pharmaceutical Company, Inc.
Treatments:
Efavirenz
Fenofibrate
Fenofibric acid